Table 1.
Promoters and Inhibitors of ASMC Migration
| Promoters | Inhibitors |
|---|---|
| PDGF [16, 17, 37, 38] | Lipoxin A2 [16] |
| TGF-β [36, 39] | PGE2 [17] |
| HB-EGF [42–44] | Corticosteroids [17, 88] |
| PGD2 [16] | Beta-Agonists [17, 88] |
| LTB4 [16, 45] | CysLT Receptor Antagonists [16, 86] |
| Eotaxin [47–50] | Leptin [97] |
| IL-8 [52] | Retinoic Acid [101] |
| CXCL2 [52] | PPAR Agonists [107–110] |
| CXCL3 [52] | Src Inhibitors [111–113] |
| IL-13 [56] | PI3K Inhibitors [16, 116–119] |
| TNF-α [56] | P38 Inhibitors [16, 120] |
| Th-17 [58] | MAPK Inhibitors [16, 120] |
| Urokinase [62, 63] | PTEN Agonists [120] |
| uPAR [65–67] | Inverse Agonism of S1P1 [100] |
| HRV-16 [84–87] | c-Abl Inhibitors [35, 121–123] |
| LTE4 [16] | |
| CCL19 [53, 54] | |
| TSLP [61] |